Iovance Biotherapeutics Inc
IOVAHealthcare|Biotechnology|USA
$4.23
-0.13 (-2.98%)
Tangible Book
$1.03
Clinical Trials (34)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05727904 Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. | Metastatic Melanoma, Unresectable Melanoma | P3 | Recruiting | 670 | RCT, Open-label | Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period |
| NCT05361174 A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | Unresectable Melanoma, Metastatic Melanoma | P1P2 | Recruiting | 53 | Open-label | IOV-4001 |
| NCT07288073 TIL Therapy in cSCC and MCC | Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma | P2 | Recruiting | 14 | Open-label | LN-145, Cyclophosphamide, Fludarabine, Interleukin-2 |
| NCT04614103 Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | P2 | Recruiting | 170 | Open-label | LN-145, LN-145 |
| NCT06481592 A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. | Endometrial Cancer | P2 | Recruiting | 60 | Open-label | Lifileucel |
| NCT07288203 A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma | Melanoma (Skin Cancer), Unresectable Melanoma | P2 | Active | 100 | Open-label | Lifileucel |
| NCT05686226 E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | Cervical Cancer, Throat Cancer | P2 | Recruiting | 20 | Open-label | E7 TCR-T cells, Aldesleukin |
| NCT05639972 E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma | P1P2 | Recruiting | 15 | Open-label | E7 TCR-T cells, Aldesleukin |
| NCT06940739 A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel | Unresectable Melanoma, Metastatic Melanoma | P1P2 | Recruiting | 42 | Open-label | IOV-3001 |
| NCT03449108 LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | Bone Sarcoma, Dedifferentiated Chondrosarcoma | P2 | Active | 30 | Open-label | Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1, Cyclophosphamide, Fludarabine, Ipilimumab, Nivolumab |
| NCT05483491 KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer | Gastric Cancer, Breast Cancer | P1 | Recruiting | 30 | Open-label | KK-LC-1 TCR-T cells, Aldesleukin |
| NCT06566092 Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants | Soft Tissue Sarcoma, Primary Central Nervous System Carcinoma | P1 | Active | 40 | Open-label | LN-145/LN-144 |
| NCT05176470 Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients | Locally Advanced Melanoma, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | P1 | Active | 2 | Open-label | Cyclophosphamide, Fludarabine, Lifileucel, Pembrolizumab |
| NCT05640193 A Study of LN-144 in People With Metastatic Melanoma to the Brain | Metastatic Melanoma | P1 | Active | 10 | Open-label | Lifileucel (LN-144) |
| NCT07192900 Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease | Malignant Pleural Effusion, Malignant Mesothelioma | P1 | Recruiting | 10 | Open-label | locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 |
| NCT05607095 A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma | Uveal Melanoma, Melanoma | P1 | Recruiting | 40 | Open-label | Lifileucel (LN-144/LN-145) |
| NCT01937468 Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease | Chronic Graft Versus Host Disease, Chronic GVHD | P1 | Active | 25 | Open-label | Interleukin-2 |
| NCT06151847 Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma | P2 | Completed | 11 | Open-label | Cyclophosphamide, Fludarabine, Interleukin-2, Lifileucel |
| NCT03419559 Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer | P2 | Withdrawn | — | Open-label | LN-145, Durvalumab |
| NCT03935347 Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy | Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma | P2 | Withdrawn | — | Open-label | Cyclophosphamide, Fludarabine, Fludarabine Phosphate, Pembrolizumab, Autologous Tumor Infiltrating Lymphocytes LN-145, Aldesleukin |
| NCT03083873 Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck | Squamous Cell Carcinoma of the Head and Neck | P2 | Completed | 64 | Open-label | LN-145, LN-145-S1 |
| NCT03108495 Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma | Cervical Carcinoma | P2 | Terminated | 210 | Open-label | LN-145, LN-145 + pembrolizumab |
| NCT04111510 Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer | Metastatic Triple Negative Breast Cancer | P2 | Completed | 6 | Open-label | Tumor infiltrating lymphocytes (TIL) LN-145 |
| NCT02360579 Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma | Metastatic Melanoma | P2 | Completed | 220 | Open-label | Lifileucel |
| NCT03645928 Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck | P2 | Terminated | 225 | Open-label | Lifileucel, LN-145, Pembrolizumab, LN-145-S1, Ipilimumab, Nivolumab, Nivolumab-relatlimab, Cisplatin, Carboplatin, Paclitaxel, Nab paclitaxel, Pemetrexed |
| NCT03610490 Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma | Malignant Solid Neoplasm, Metastatic Colorectal Adenocarcinoma | P2 | Terminated | 16 | Open-label | Autologous Tumor Infiltrating Lymphocytes MDA-TIL, Cyclophosphamide, Fludarabine, Interleukin-2 |
| NCT04155710 Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | P1 | Completed | 7 | Open-label | IOV-2001, Low dose IL-2, High dose IL-2, IL-2 |
| NCT06190249 Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma | Stage IIIB Melanoma, Stage IIIC Melanoma | P1 | Withdrawn | — | Open-label | LN-144, Cyclophosphamide, Mesna, Fludarabine, Interleukin-2 (IL-2), Pembrolizumab |
| NCT04052334 Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma | Sarcoma | P1 | Completed | 9 | Open-label | TIL, Interleukin-2, Fludarabine, Cyclophosphamide |
| NCT03215810 Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer | P1 | Completed | 20 | Open-label | Nivolumab, Cyclophosphamide, Fludarabine, Interleukin-2 (IL2) |
| NCT07700121 PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma | Unresectable or Metastatic Melanoma | Early P1 | Not Yet Recruiting | 10 | Open-label | Lifileucel Manufacturing Clinical v Research, Chemotherapy Regimen, Lifileucel Infusion, IL-2 |
| NCT02652455 Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma | Melanoma (Skin), Skin Cancer | Early P1 | Completed | 11 | Open-label | Nivolumab, CD137, Cyclophosphamide, Fludarabine, TIL Infusion, Interleukin-2 |
| NCT05398640 Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release | Unresectable Melanoma, Metastatic Melanoma | AVAILABLE | — | — | OOS AMTAGVI | |
| NCT01701674 Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts | Metastatic Melanoma | N/A | Completed | 13 | Open-label | Ipilimumab, Administration of Lymphodepletion, Cyclophosphamide as Part of Lymphodepletion, Fludarabine as Part of Lymphodepletion, High Dose IL-2, Adoptive Cell Therapy with TIL |